NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines

Active specific immunotherapy is a promising field in cancer research. N-glycolyl (NGc) gangliosides, and particularly NGcGM3, have received attention as a privileged target for cancer therapy. Many clinical trials have been performed with the anti-NGc-containing gangliosides anti-idiotype monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez, Luis E., Gabri, Mariano R., Guthmann, Marcelo D., Gomez, Roberto E., Gold, Silvia, Fainboim, Leonardo, Gomez, Daniel E., Alonso, Daniel F.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2965427/
https://www.ncbi.nlm.nih.gov/pubmed/21048926
http://dx.doi.org/10.1155/2010/814397
Descripción
Sumario:Active specific immunotherapy is a promising field in cancer research. N-glycolyl (NGc) gangliosides, and particularly NGcGM3, have received attention as a privileged target for cancer therapy. Many clinical trials have been performed with the anti-NGc-containing gangliosides anti-idiotype monoclonal antibody racotumomab (formerly known as 1E10) and the conjugated NGcGM3/VSSP vaccine for immunotherapy of melanoma, breast, and lung cancer. The present paper examines the role of NGc-gangliosides in tumor biology as well as the available preclinical and clinical data on these vaccine products. A brief discussion on the relevance of prioritization of cancer antigens in vaccine development is also included.

Ejemplares similares